Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 7, 2023Annals of Clinical and Translational NeurologyOpen Access

A blood biomarker test for brain amyloid impacts the clinical evaluation of cognitive impairment

View Full Paper
Ask AI
Bookmark
Share

Authors

MMMark MonaneKJKim G. JohnsonBSB. Joy Snider

Discussion

Loading...

Member takes

Overview

Randomized trial evaluates blood biomarkers for cognitive impairment diagnosis, highlighting clinical significance.

Key Points

  • This study aimed to assess how a blood biomarker test influences clinician decisions in diagnosing cognitive decline.
  • Prospective, single-arm cohort study with 366 symptomatic patients
  • Patients underwent PrecivityAD blood testing to assess amyloid beta and ApoE levels
  • Evaluation of clinician patient selection and result interpretation based on amyloid probability score (APS)
  • 95% concordance rate between clinician selection and intended test use
  • AD diagnosis probability changed significantly: low APS patients from 58% to 23%, high APS from 71% to 89% (p < 0.0001)
  • Anti-AD drug therapy decreased by 46% in low APS patients and increased by 57% in high APS patients (p < 0.0001)

Cite This Study

Monane et al. (2023) studied this question.

synapsesocial.com/papers/6a61ef310579a17fd4c930c8https://doi.org/10.1002/acn3.51863
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Lecanemab in Early Alzheimer’s Disease2022 · 5,711 citations
  2. 2The PrecivityAD™ test: Accurate and reliable LC-MS/MS assays for quantifying plasma amyloid beta 40 and 42 and apolipoprotein E proteotype for the assessment of brain amyloidosis2021 · 137 citations
  3. 3Validation of Plasma Amyloid-β 42/40 for Detecting Alzheimer Disease Amyloid Plaques2021 · 196 citations
  4. 4Effectiveness of Florbetapir PET Imaging in Changing Patient Management2017 · 48 citations
  5. 5Association of Amyloid Positron Emission Tomography With Subsequent Change in Clinical Management Among Medicare Beneficiaries With Mild Cognitive Impairment or Dementia2019 · 678 citations